The concentration allowance for the opioid alkaloid 7-hydroxymitragynine in retail kratom products was raised twentyfold above initial recommendations

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.